Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we
summarize the different therapeutic mAbs that have been successfully developed against …

Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Since the advent of hybridoma technology, dating back to 1975, monoclonal antibodies
have become an irreplaceable diagnostic and therapeutic tool for a wide array of human …

In 1997, for the first time in history, a monoclonal antibody (mAb), ie, the chimeric anti-CD20
molecule rituximab, was approved by the US Food and Drug Administration for use in …

During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that
antibodies possess several clinically relevant mechanisms of action. Many clinically useful …

Over the past decade, the clinical utility of monoclonal antibodies has been realized and
antibodies are now a mainstay for the treatment of cancer. Antibodies have the unique …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable
success in recent years. Antibody–drug conjugates are powerful new treatment options for …

Targeted therapies like treatment with monoclonal antibodies (mAbs) have entered the
arsenal of modern anticancer drugs. mAbs combine specificity with multiple effector …